# New Zealand Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore New Zealand HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: New Zealand (NZL)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $169.5M
- Products: 38
- Buyer markets: 27
- Average CAGR: +16.1%
- Global sector size: $741.4B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $310.3B | $55.5M | $116.6B | +12.0% | 22 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $155.9B | $4.0M | $62.2B | +15.2% | 15 | +0.0% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $19.3B | $81.2K | $33.8B | +9.8% | 3 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $28.6B | $7.8K | $33.3B | +49.4% | 4 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $24.9B | $630.3K | $20.9B | +29.2% | 5 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $21.8B | $4.8M | $16.1B | +15.0% | 7 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $28.0B | $53.9M | $16.1B | +19.1% | 6 | +0.4% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $26.0B | $4.4M | $15.9B | +46.3% | 8 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.8B | $32.5K | $11.7B | +9.0% | 2 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $300.1K | $10.7B | +7.0% | 3 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $11.9B | $346.4K | $7.4B | +16.3% | 2 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $4.9M | $6.3B | +21.8% | 3 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $7.8B | $630.1 | $6.3B | -40.4% | 2 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $37.8M | $5.8B | +23.8% | 2 | +0.3% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $5.6B | $49.7 | $4.3B | +7.7% | 2 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $738.8 | $4.1B | -14.4% | 2 | +0.0% |
| HS 283691 - Carbonates: lithium carbonate | $2.5B | $173.0 | $3.8B | -60.1% | 1 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $4.5B | $2.9K | $3.8B | +1.5% | 2 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $37.1K | $3.3B | +7.6% | 2 | +0.0% |
| HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $3.2B | $14.0K | $3.1B | +128.3% | 1 | +0.0% |
| HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $873.2 | $2.4B | +23.3% | 1 | +0.0% |
| HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $101.0 | $2.4B | -4.1% | 1 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $1.5B | $20.4K | $2.1B | +5.3% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $1.3M | $2.0B | +10.1% | 1 | +0.0% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $905.0K | $2.0B | +2.7% | 1 | +0.0% |
| HS 284590 - Isotopes (excluding those of heading no. 2844): compounds, inorganic or organic, of such isotopes, whether or not chemically defined | $1.1B | $14.5K | $1.9B | +6.1% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $165.3K | $1.9B | +100.4% | 1 | +0.0% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $2.2B | $157.6 | $1.8B | -47.4% | 1 | +0.0% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $566.9 | $1.8B | +21.4% | 1 | +0.0% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $1.1B | $160.7K | $1.6B | -1.5% | 1 | +0.1% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $1.9B | $2.9K | $1.5B | +28.0% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $120.3 | $1.4B | -12.6% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $582.9 | $1.4B | -2.2% | 1 | +0.0% |
| HS 293722 - Steroidal hormones, their derivatives and structural analogues: halogenated derivatives of corticosteroidal hormones | $1.5B | $881.8 | $1.3B | -24.3% | 1 | +0.0% |
| HS 310221 - Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | $965.4M | $26.8 | $1.3B | +1.7% | 1 | +0.0% |
| HS 290110 - Acyclic hydrocarbons: saturated | $916.4M | $55.8K | $1.3B | +70.7% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $117.0K | $1.2B | +9.1% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $290.7 | $1.1B | -11.2% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $153.8B calculated opportunity across 21 products.
- Switzerland, Liechtenstein (CHE): $36.6B calculated opportunity across 4 products.
- Germany (DEU): $34.6B calculated opportunity across 11 products.
- China (CHN): $31.0B calculated opportunity across 11 products.
- Netherlands (NLD): $19.6B calculated opportunity across 5 products.
- Belgium (BEL): $16.1B calculated opportunity across 3 products.
- Canada (CAN): $13.2B calculated opportunity across 7 products.
- Slovenia (SVN): $12.8B calculated opportunity across 2 products.
- United Kingdom (GBR): $12.3B calculated opportunity across 6 products.
- Mexico (MEX): $11.8B calculated opportunity across 6 products.
- Italy (ITA): $9.8B calculated opportunity across 2 products.
- Spain (ESP): $9.0B calculated opportunity across 4 products.

## Growth stars

- HS 310420: +128.3% average CAGR, $3.1B calculated opportunity.
- HS 382319: +100.4% average CAGR, $1.9B calculated opportunity.
- HS 290110: +70.7% average CAGR, $1.3B calculated opportunity.
- HS 300214: +49.4% average CAGR, $33.3B calculated opportunity.
- HS 300439: +46.3% average CAGR, $15.9B calculated opportunity.
- HS 300220: +29.2% average CAGR, $20.9B calculated opportunity.
- HS 293590: +28.0% average CAGR, $1.5B calculated opportunity.
- HS 330499: +23.8% average CAGR, $5.8B calculated opportunity.
- HS 290121: +23.3% average CAGR, $2.4B calculated opportunity.
- HS 382200: +21.8% average CAGR, $6.3B calculated opportunity.

## Diversification opportunities

- HS 300490: 22 buyer markets, $116.6B calculated opportunity.
- HS 300215: 15 buyer markets, $62.2B calculated opportunity.
- HS 300439: 8 buyer markets, $15.9B calculated opportunity.
- HS 382499: 7 buyer markets, $16.1B calculated opportunity.
- HS 300212: 6 buyer markets, $16.1B calculated opportunity.
- HS 300220: 5 buyer markets, $20.9B calculated opportunity.
- HS 300214: 4 buyer markets, $33.3B calculated opportunity.
- HS 293719: 3 buyer markets, $33.8B calculated opportunity.
- HS 330210: 3 buyer markets, $10.7B calculated opportunity.
- HS 382200: 3 buyer markets, $6.3B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.